Tubulointerstitial damage and interstitial immune cell phenotypes are useful predictors for renal survival and relapse in antineutrophil cytoplasmic antibody-associated vasculitis.


Journal

Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 27 09 2019
accepted: 26 12 2019
pubmed: 10 1 2020
medline: 3 8 2021
entrez: 10 1 2020
Statut: ppublish

Résumé

The aims of this study were to determine whether tubulointerstitial damage in the form of interstitial fibrosis/tubular atrophy and total interstitial inflammation predicted progression to end stage renal disease (ESRD) and/or renal relapse (RR) in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). One hundred thirteen patients with AAV from six French centers with an index biopsy performed between 2003 and 2013 were included. Histological assessments using the AAV glomerular classification and the kidney allograft Banff classification were performed on pathological review. Biopsy tissues were also investigated by CD3, CD20, CD68, CD163, FOXP3 and RORγt immunohistochemical staining. Competing risks models were calculated. Of the 113 patients, 26 (23.0%) died during follow-up and 29 (25.6%) developed ESRD. Among the 94 patients who achieved remission by the end of induction therapy without developing ESRD, 26 (27.6%) experienced RR. The two independent prognostic factors for ESRD were the estimated glomerular filtration rate at presentation (HR 0.35; 95% CI 0.23-0.51; P < 0.0001) and IF/TA > 25% (HR 2.27; 95% CI 1.18-4.37; P = 0.014). When the distribution of interstitial immune cell phenotypes was included in a second multivariable model, the organization of lymphocytic infiltrates was also an independent predictor of ESRD (HR 2.86; 95% CI 1.35-6.1, P = 0.006). The independent risk factors for RR were a higher CD3/CD20 ratio (HR 1.39; 95% CI 1.05-1.85; P = 0.02) and the presence of RORγt positive cells (HR 2.70; 95% CI 1.11-6.54; P = 0.02). Our results highlight the prognostic value of initial histological evaluations in AAV. Measurements of tubulointerstitial damage and interstitial immune cell phenotype distributions should be considered to improve risk assessments for ESRD and RR.

Identifiants

pubmed: 31916228
doi: 10.1007/s40620-019-00695-y
pii: 10.1007/s40620-019-00695-y
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

771-781

Auteurs

Laura Bitton (L)

Pathology Department, AP-HP, Hôpital Tenon, 75020, Paris, France.

Cyrille Vandenbussche (C)

Nephrology and Internal Medicine Department, Hospital of Valenciennes, 59322, Valenciennes, France.

Nicolas Wayolle (N)

Nephrology Department, Univ. Lille, CHU Lille, 59000, Lille, France.

Jean-Baptiste Gibier (JB)

Pathology Department, Lille University Hospital (CHU), Pathology Institute, Inserm UMR-S1172 Lille, JPARC-Jean-Pierre Aubert Research Center, Team 'Mucins, Epithelial Differentiation and Carcinogenesis", Lille University, CHU Lille, Avenue Oscar Lambret, 59000, Lille, France.

Carole Cordonnier (C)

Pathology Department, Amiens University Hospital, 80054, Amiens, France.

Jérôme Verine (J)

Hôpital Saint-Louis Pathology Department, AP-HP, 75010, Paris, France.

Sarah Humez (S)

Pathology Department, CNRS, Institut Pasteur de Lille, UMR 8161-M3T "Mechanisms of Tumorigenesis and Targeted Therapies", Univ. Lille, CHU Lille, 59000, Lille, France.

Pierre Bataille (P)

Nephrology Department, Hospital of Boulogne-Sur-Mer, 62200, Boulogne-sur-Mer, France.

Rémi Lenain (R)

EA 2694-Santé Publique : épidémiologie Et qualité Des Soins, Univ. Lille, CHU Lille, 59000, Lille, France.

Nassima Ramdane (N)

EA 2694-Santé Publique : épidémiologie Et qualité Des Soins, Univ. Lille, CHU Lille, 59000, Lille, France.

Raymond Azar (R)

Nephrology Department, Hospital of Dunkerque, 59385, Dunkerque, France.

Evelyne Mac Namara (E)

Nephrology Department, Hospital of Béthune-Beuvry, 62408, Béthune, France.

Pierre-Yves Hatron (PY)

Internal Medicine Department, Univ. Lille, CHU Lille, 59000, Lille, France.

Claude-Alain Maurage (CA)

Pathology Department, Univ. Lille, Inserm, CHU Lille, UMR-S 1172 - JPARC - Jean-Pierre Aubert Research Center, Team "Alzheimer & Tauopathies", 59000, Lille, France.

Michael Perrais (M)

Pathology Department, Lille University Hospital (CHU), Pathology Institute, Inserm UMR-S1172 Lille, JPARC-Jean-Pierre Aubert Research Center, Team 'Mucins, Epithelial Differentiation and Carcinogenesis", Lille University, CHU Lille, Avenue Oscar Lambret, 59000, Lille, France.

Marie Frimat (M)

Nephrology Department, Univ. Lille, CHU Lille, 59000, Lille, France.

Philippe Vanhille (P)

Nephrology and Internal Medicine Department, Hospital of Valenciennes, 59322, Valenciennes, France.

François Glowacki (F)

Nephrology Department, Univ. Lille, CHU Lille, 59000, Lille, France.

David Buob (D)

Pathology Department, AP-HP, Hôpital Tenon, 75020, Paris, France.

Marie-Christine Copin (MC)

Pathology Department, CNRS, Institut Pasteur de Lille, UMR 8161-M3T "Mechanisms of Tumorigenesis and Targeted Therapies", Univ. Lille, CHU Lille, 59000, Lille, France.

Thomas Quéméneur (T)

Nephrology and Internal Medicine Department, Hospital of Valenciennes, 59322, Valenciennes, France.

Viviane Gnemmi (V)

Pathology Department, Lille University Hospital (CHU), Pathology Institute, Inserm UMR-S1172 Lille, JPARC-Jean-Pierre Aubert Research Center, Team 'Mucins, Epithelial Differentiation and Carcinogenesis", Lille University, CHU Lille, Avenue Oscar Lambret, 59000, Lille, France. viviane.gnemmi@univ-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH